Oral Candida dubliniensis as a clinically important species in HIV-seropositive patients in the United States

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 88, Issue 5, 1999, Pages 573-580

  Meiller, Timothy F ^a,d   Jabra Rizk, Mary Ann ^a   Baqui, A A M A ^a   Kelley, Jacqueline I ^a   Meeks, Valli I ^a   Merz, William G ^b   Falkler, William A ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^d UMB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; FUNGAL DNA;

ARTICLE; CANDIDA; CLASSIFICATION; FEMALE; GENETICS; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; KARYOTYPING; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PERIODONTAL DISEASE; PROSPECTIVE STUDY; THRUSH; VIRUS LOAD;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, ORAL; DMF INDEX; DNA, FUNGAL; FEMALE; FLUCONAZOLE; HIV SEROPOSITIVITY; HUMANS; KARYOTYPING; MALE; MICROBIAL SENSITIVITY TESTS; PERIODONTAL DISEASES; PROSPECTIVE STUDIES; VIRAL LOAD;

EID: 0033227161     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1079-2104(99)70088-0     Document Type: Article

References (53)

1. Bartlett JG. Medical management of HIV infection. Baltimore: Johns Hopkins University School of Medicine; 1998.
2. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. AIDS 1991;4:770-6.
3. Crowe SM, Vardaxis NJ, Kent SJ, Maerz AL, Hewish MJ, McGrath MS, et al. HIV infection of monocyte-derived macrophages in vitro reduces phagocytosis of Candida albicans. J Leukoc Biol 1994;56:318-27.
4. Crowe SM, Kornbluth RS. How HIV leads to opportunistic infections. Med J Aust 1996;164:171-3.
5. Hicks MJ, Carter AB, Rossmann SN, Demmler GJ, Simon CL, Cron SG, et al. Detection of fungal organisms in saliva from HIV-infected children: a preliminary cytologic analysis. Pediatr Dent 1998;20:162-8.
6. Kirkpatrick WR, Revankar SG, McAtee RK, Lopez-Ribot JL, Fothergill AW, McCarthy DI, et al. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected pateints in North America by primary CHROMagar Candida screening and susceptibility testing of isolates. J Clin Microbiol 1998;36:3007-12.
7. Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med 1984;31:354-8.
8. Caliendo AM. Methods, interpretation and application of HIV-1 viral load measurements. Clinical Microbiology Newsletter 1997;19:1-5.
9. Kempf DJ, Rode RA, Xu Y, Sun E, Heath-Chiozzi ME, Valdes J, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998;12:F9-F14.
10. Mellors JW, Alvaromunoz, Giorgi JV, Margokick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV infection. Ann Int Med 1997;126:946-54.
11. Tetali S, Bakshi S, Pahwa S, Abrams E, Romano J, Pahwa SG. Plasma virus load evaluation in relation to disease progression in HIV-infected children. AIDS Res Hum Retroviruses 1998;14:571-7.
12. Mellors JW, Kingsley LA, Rinaldo CR, Todd JA, Hoo BS, Kokka RP, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Int Med 1995;122:573-9.
13. Greenspan D, Greenspan JS. Oral manifestations of human immunodeficiency virus infection. Dent Clin North Am 1993;37:21-32.
14. Mirowski GW, Hilton JF, Greenspan D, Canchola AJ, Macphail L, Maurer T, et al. Association of cutaneous and oral diseases in HIV-infected men. Oral Dis 1998;4:16-21.
15. Barr CE, Lopex MR, Rua-Dobles A, Miller LK, Mathur-Wagh U, Turgeon LR. HIV-associated oral lesions; immunologic, virologic and salivary parameters. Oral Pathol Med 1992;21:295-8.
16. Jabra-Rizk MA, Baqui AAMA, Kelley JI, Falkler WA, Jr, Merz WG, Meiller TF. Identification of Candida dubliniensis in a prospective study of patients in the United States. J Clin Microbiol 1999;37:321-6.
17. Merz WG. Candida albicans strain delineation. Clin Microbiol Rev 1990;3:321-34.
18. Merz WG, Khazan U, Jabra-Rizk MA, Wu L-C, Osterhout GJ, Lehmann PF. Strain delineation and epidemiology of Candida (Clavispora) lusitaniae. J Clin Microbiol 1992;30:449-54.
19. Vazquez JA, Dembry LM, Sanchez V, Vazquez, MA, Sobel JD, Dmuchowski C, et al. Nosocomial Candida glabrata colonization: an epidemiologic study. J Clin Microbiol 1998;36:421-6.
20. Wingard J, Merz W, Saral R. Candida tropicalis:a major pathogen in immunocompromised patients. Ann Int Med 1979;91:529-43.
21. Wingard JR, Merz WG, Rinaldi G, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;18:1274-7.
22. Sullivan D, Bennett D, Henman M, Harwood P, Flint S, Mulcahy D, et al. Oligonucleotide fingerprinting of isolates of Candida species other than C albicans and of atypical Candida species from human immunodeficiency virus-positive and AIDS patients. J Clin Microbiol 1993;31:2124-33.
23. Sullivan D, Westermemg T, Haynes KA, Bennett D, Coleman D. Candida dubliniensis sp. nov. Iphenotypic and molecular characterization of a novel species associated with oral candidiasis in HIV-infected individuals. Microbiology 1995;141:1507-21.
24. Boerlin P, Loerlin-Petzold F, Durussel C, Addo M, Pagani JL, Chave JP, et al. Cluster of oral atypical Candida albicans isolates in a group of human immunodeficiency virus-positive drug users. J Clin Microbiol 1995;33:1129-35.
25. Coleman DC, Sullivan DJ, Bennett DE, Moran GP, Barry HJ, Shanky DB. Candidiasis: the emergence of a novel species, Candida dubliniensis. AIDS 1997;11:557-67.
26. McCullough M, Ross B, Reade P. Characterization of genetically distinct subgroup of Candida albicans strains isolated from oral cavities of patients infected with human immunodeficiency virus. J Clin Microbiol 1995;33:696-700.
27. Moran GP, Sullivan DJ, Henman MC, McCreary E, Harrington BJ, Shanley DB, et al. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HlV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother 1997;41:617-23.
28. Sullivan D, Haynes K, Bille J, Boerlin P, Rodero L, Lloyd S, et al. Widespread geographic distribution of oral Candida dubliniensis strains in human immunodeficiency virus-infected individuals. J Clin Microbiol 1997;35:960-4.
29. Schoofs A, Odds FC, Colebunders R, Ieven M, Goosens H. Use of specialised isolation media for recognition and identification of Candida dubliniensis isolates from HIV-infected patients. Eur J Clin Microbiol Infect Dis 1997;16:296-300.
30. Sullivan DJ. Presentation: molecular epidemiological analysis of Candida dubliniensis, a newly described pathogen. 98th General Meeting of the American Society of Microbiology; Atlanta, Ga; May-June 1998.
31. Sullivan D, Coleman D. Candida dubliniensis: characteristics and identification. J Clin Microbiol 1998;36:329-34.
32. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH. Manual of clinical microbiology. 6th ed. Washington: ASM Press; 1995. p. 723-37.
33. Odds FC, Van Nuffel L, Dams G. Prevalence of Candida dubliniensis isolates in a yeast stock collection. J Clin Microbiol 1998;36:2869-73.
34. Pinjon E, Sullivan D, Salkin I, Shanley D, Coleman D. Simple, inexpensive, reliable method for differentiation of Candida dubliniensis from Candida albicans. J Clin Microbiol 1998;36:2093-5.
35. Elie CM, Lasker BA, Mayer LW, Pruitt WR, Smith G, Rimland D, et al. Rapid differentiation of Candida dubliniensis from atypical C albicans isolates using species-specific DNA probes. 98th General Meeting of the American Society for Microbiology; Atlanta, Ga; May 1998. Washington DC: ASM Press; 1998.
36. Laguna F, Rodriguez-Tudela JL, Martinez-Suarez JV, Polo R, Valencia E, Diaz-Guerra TM, et al. Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans. Clin Infect Dis 1997;24:124-30.
37. Odds FC, Bernaerts R. CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. J Clin Microbiol 1994;32:1923-9.
38. King D, Rhine-Chalberg J, Pfaller MA, Moser SA, Merz WG. Comparison of four DNA-based methods for strain delineation of Candida lusitaniae. J Clin Microbiol 1995;33:1467-70.
39. The National Committee for Clinical Laboratory Standards. Standard NCCLS Document MATP: reference method for broth dilution antifungal susceptibility testing of yeasts: proposed time is 48 hours to 72 hours. Report #5. Vol 12; 1992.
40. Isenberg HD. In vitro antifungal susceptibility testing of yeasts. In: Clinical microbiology procedures handbook. Vol 1. Washington: ASM; 1992. p. 5.15.1-5.15.16.
41. Gilfillan GD, Sullivan DJ, Haynes K, Parkinson T, Coleman DC, Gow NAR. Candida dubliniensis: phylogeny and putative virulence factors. Microbiology 1998;144:829-38.
42. Hunter KD, Gibson J, Lockhart P, Pithie A, Bagg J. Fluconazole-resistant Candida species in the oral flora of fluconazole-exposed HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:558-64.
43. Moran GP, Sanglard D, Donnelly SM, Shanley DB, Sullivan DJ, Coleman DC. Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother 1998;42:1819-30.
44. Pfaller MA, Messer SA, Gee S, Joly S, Pujol C, Sullivan DJ, et al. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol 1999;37:870-2.
45. Porter SR, Luker J, Scully C. Demographics of HIVinfected persons attending a dental clinic. Br Dent J 1996;180:303-6.
46. Glick M, Muzykia BC, Lurie D, Salkin LM. Oral manifestations associated with HIV-related disease as markers for immune suppression and AIDS. Oral Surg Oral Med Oral Pathol 1994;77:344-9.
47. Scully C, Porter SR. Oral mucosal disease: a decade of new entities, aetiologies and associations. Int Dent J 1994;44:33-43.
48. Weinert M, Grimes RM, Lynch DP. Oral manifestations of HIV infection. Ann Intern Med 1996;125:485-96.
49. Brady LJ, Walker C, Oxford GE, Stewart C, Magnusson I, McArthur W. Oral diseases, mycology and periodontal microbiology of HIV-1 infected woman. Oral Microbiol Immunol 1996;11:371-80.
50. Foltyn P. HIV-related oral disease. Med J Aus 1993;158:109-10.
51. Gehri R, Hahn S, Rothen M, Steuerwald M, Nuesch R, Erb P. The Fas receptor in HIV infection: expression on peripheral blood lymphocytes and role in the depletion of T cells. AIDS 1996;10:9-16.
52. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
53. Klein H, Palmer CE. Dental caries in American Indian children. Washington DC: US Public Health Bulletin: US Public Health Service 1937; p. 239.